Shenzhen Chipscreen Biosciences (688321.SH): CS43158 tablets received the drug clinical trial approval notice.
Shenzhen Chipscreen Biosciences (688321.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of the company's product CS43158 tablets for acute myeloid leukemia. CS43158 is a multi-target protein kinase inhibitor that simultaneously covers the driver oncogenic pathways and bypass-activated resistance pathways of acute myeloid leukemia (AML), with the dual effect of targeting primary driver mutations and overcoming secondary resistance.
Shenzhen Chipscreen Biosciences (688321.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company's product CS43158 tablets to conduct clinical trials for acute myeloid leukemia. CS43158 is a multi-target protein kinase inhibitor that can simultaneously cover both the driver oncogenic pathways and bypass-activated resistance pathways of acute myeloid leukemia (AML), possessing the dual effect of targeting primary driver mutations and overcoming secondary resistance.
Related Articles
US Stock Market Move | Muse's user retention level approaches ChatGPT; Meta (META.US) rises over 3% in early trading.
CALB (03931): The CSRC issues a filing notice regarding the Company's implementation of full circulation of H shares.
CR BLDG MAT TEC (01313) issues profit warning, expects loss attributable to owners of the company of approximately RMB 750 million to RMB 850 million for the first nine months, turning from profit to loss year-on-year.
US Stock Market Move | Muse's user retention level approaches ChatGPT; Meta (META.US) rises over 3% in early trading.
CALB (03931): The CSRC issues a filing notice regarding the Company's implementation of full circulation of H shares.
CR BLDG MAT TEC (01313) issues profit warning, expects loss attributable to owners of the company of approximately RMB 750 million to RMB 850 million for the first nine months, turning from profit to loss year-on-year.
